Bolt Biotherapeutics Q3 2024: cash $84.4M; BDC-3042 advances to 10 mg/kg cohort

Bolt Biotherapeutics, Inc.

2024-Q3 EPS reported -$1.24 revenue$7,690,000

Cash $84.4M as of Sept 30, 2024; expected to fund operations through mid-2026.
Q3 operating loss $16.4M vs $18.2M in Q3 2023; R&D expenses $13.8M, G&A $3.8M.
BDC-3042 Phase 1 advanced to 10 mg/kg cohort; data update expected H1 2025.
BDC-4182 on track for clinical trial start in Q2 2025; preclinical data at SITC.
Collaboration revenue $1.1M, down from $2.5M in prior-year quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.